Syndax Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	0	0	139.71	1.52	1.52	1.52	2.11	1.22	0.63	0
Revenue Growth (YoY)	-	-	9109.56%	0%	0%	-28.04%	72.79%	94.58%	-	-
Gross Profit	0	0	139.71	1.52	1.52	1.52	2.11	1.22	0.63	0
Selling, General & Admin	66.92	33.26	25.24	22.51	16.06	17.29	15.86	13.32	11.59	11.16
Research & Development	163.03	118.5	88.25	50.44	42.99	60.11	48.2	31.67	9.55	10.18
Operating Expenses	229.95	151.76	113.49	72.94	59.06	77.39	64.06	44.99	21.14	21.33
Operating Income	-229.95	-151.76	26.22	-71.42	-57.54	-75.88	-61.95	-43.77	-20.51	-21.33
Interest Expense / Income	0.21	3.14	1.9	2.36	0	0	-1.42	-0.96	1.41	0.29
Other Expense / Income	-20.8	-5.56	-0.61	3.28	-1.49	-1.92	0.27	4.26	81.92	4.74
Pretax Income	-209.36	-149.34	24.93	-77.06	-56.05	-73.96	-60.8	-47.07	-103.85	-26.36
Net Income	-209.36	-149.34	24.93	-77.06	-56.05	-73.96	-60.8	-47.07	-103.85	-26.36
Shares Outstanding (Basic)	70	61	52	41	30	25	21	15	0	0
Shares Outstanding (Diluted)	70	61	54	41	30	25	21	15	0	0
Shares Change	15.82%	13.31%	29.81%	35.48%	20.18%	20.83%	43.62%	21288.86%	17.48%	-
EPS (Basic)	-2.98	-2.46	0.48	-1.87	-1.84	-2.92	-2.90	-3.22	-1519.27	-453.02
EPS (Diluted)	-2.98	-2.46	0.46	-1.87	-1.84	-2.92	-2.90	-3.22	-1519.27	-453.02
Free Cash Flow	-160.6	-133.45	29	-71.26	-50.61	-68.72	-47.46	-35.42	-2.48	-14.4
Free Cash Flow Per Share	-2.28	-2.20	0.56	-1.73	-1.66	-2.71	-2.26	-2.42	-36.24	-247.45
Gross Margin	-	-	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-	-	18.77%	-4708.17%	-3792.95%	-5001.71%	-2938.99%	-3587.38%	-3271.61%	-
Profit Margin	-	-	17.84%	-5080.03%	-3694.59%	-4875.48%	-2884.35%	-3858.20%	-16562.20%	-
Free Cash Flow Margin	-	-	20.76%	-4697.43%	-3336.32%	-4529.86%	-2251.19%	-2903.11%	-395.06%	-
EBITDA	-208.4	-145.75	27.28	-74.19	-55.6	-73.88	-62.15	-47.94	-102.41	-26.05
EBITDA Margin	-	-	19.53%	-4890.71%	-3664.86%	-4870.34%	-2948.15%	-3929.26%	-16333.33%	-
Depreciation & Amortization	0.75	0.45	0.46	0.52	0.45	0.08	0.08	0.09	0.02	0.02
EBIT	-209.15	-146.2	26.83	-74.71	-56.05	-73.96	-62.22	-48.03	-102.43	-26.07
EBIT Margin	-	-	19.20%	-4924.65%	-3694.59%	-4875.48%	-2951.76%	-3936.56%	-16336.68%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).